Prostat Kanserinde Hormonoterapi Alan ve Almayan Hastaların Fiziksel Aktivite, Egzersiz Kapasitesi, Yaşam Kalitesi ve Yorgunluk Düzeylerinin Karşılaştırılması
Danış, Şükran Mine
Ambargo Süresi6 ay
Üst veriTüm öğe kaydını göster
Physical activity level, exercise capacity, quality of life and fatigue level may be affected in prostate cancer patients receiving hormonal therapy. The aim of our study was to evaluate the physical activity, exercise capacity, quality of life and fatigue levels of prostate cancer patients who received hormone therapy, and to compare them with prostate cancer patients who did not receive hormone therapy and healthy individuals. Twenty prostate cancer patients receiving androgen deprivation therapy, 20 prostate cancer patients not receiving androgen deprivation therapy, and 20 healthy individuals who were similar in age, height and weight were included in the study. The physical and demographic characteristics of the participants were recorded. In the evaluation of the participants, the exercise capacity was evaluated by the six-minute walk test (6MWT) and the ten-meter walking test, the physical activity level was evaluated by the International Physical Activity Questionnaire (IPAQ), the fatigue level was evaluated by the Fatigue Severity Scale (FSS), and the quality of life was evaluated by European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and prostate cancer module (EORTC QLQ PR-25). The Senior Fitness Test (SFT) was used to assess physical fitness, the Timed Up and Go Test (TUG) and Berg Balance Scale (BBS) were used for balance assessment, and the Barthel ADL Index was used for activities of daily living. Lower body muscle strength was evaluated with the 30 sec Sit and Stand Test, and grip strength was evaluated with a Jamar hand dynamometer. As a result of the study, 6MWT distance, quality of life scores, grip strength measurement, parameters of SFT; biceps curl test, sit-to-stand test repetitions and BBS scores of prostate cancer patients receiving androgen deprivation therapy (ADT) were found to be significantly lower than the other groups (p<0.05). In prostate cancer patients who received ADT, the duration of the ten-meter walk test, TUG time, and parameter of the SFT; the 8-foot up an go test time were significantly higher than the other groups (p<0.05). There was no significant difference between the three groups in terms of IPAQ scores, the chair sit and reach test, and the back scratch test of the left upper extremity (p>0.05). In conclusion, balance, exercise capacity and fatigue aresignificantly affected in prostate cancer patients receiving hormone therapy compared to healthy individuals. By evaluating the physical fitness and functional capacities of prostate cancer patients receiving hormonal therapy in the early period, it will guide in planning physiotherapy and rehabilitation programs suitable for the individual and in coping with the side effects of androgen deprivation therapy.